Pre-Filled Syringes Market - 2025-2033

Pre-Filled Syringes Market Size

Pre-Filled Syringes Market Size reached US$ 8.66 Billion in 2024 and is expected to reach US$ 30.04 Billion by 2033, growing at a CAGR of 15.5% during the forecast period 2025-2033.

Pre-Filled Syringes Market Pre-filled syringes are ready-to-use medical devices containing a pre-measured medication or vaccine dose. These syringes come pre-loaded with a specific amount of a drug, making them convenient for healthcare professionals and patients. The pre-filled syringe typically consists of a syringe barrel, a plunger, and a needle or a needle shield.

Some pre-filled syringes come with safety features, such as needle shields or retractable needles, to enhance safety during use and disposal. Pre-filled syringes often have a longer shelf life compared to some traditional forms of medication packaging, as they can protect the drug from environmental factors.

The rise of self-care interventions has played a significant role in driving the demand for pre-filled syringes in the healthcare market. Self-administration of medications is becoming increasingly common as people take a more active role in managing their health. For instance, according to Harvard University, 7 billion prefilled syringes are used annually around the world.

Additionally, according to the Study conducted by the National Institute of Health (NIH), in total, 234 patients completed the questionnaire. Half (50%) of the patients were willing to self-administer medication. However, 37% of patients preferred self-administration of medication over nurse-led medication administration. Pre-filled syringes offer a user-friendly solution, eliminating the need for complex dosage measurements and making it easier for individuals to self-administer their medications.

Pre-Filled Syringes Market Dynamics: Drivers & Restraints

The rising popularity of self-administration is significantly driving the pre-filled syringes market growth

Self-administration allows patients to inject medications in the comfort of their homes, which is particularly important for chronic conditions such as diabetes, rheumatoid arthritis, and multiple sclerosis. This convenience reduces the need for frequent hospital visits, thus saving time and costs for both patients and healthcare providers.

For instance, according to the study conducted by the National Institute of Health (NIH), the majority (62%) of the diabetes study patients had a favorable attitude toward insulin self-administration. Although the majority of 177(72.2%) of the study patients have administered insulin themselves, only 120(49.0%) of the patients injected insulin appropriately at 45 degrees.

According to the International Diabetes Federation estimated that diabetes will reach 592 million in the year 2035. Similarly, there were more than 1.8 million diabetes patients in Ethiopia, with a national prevalence of 4.36% among the adult population. This rising diabetes increases the demand for insulin self-administration, which in turn increases the demand for prefilled syringes.

The growth of home healthcare services is closely tied to the self-care trend. Pre-filled syringes fit well within the home healthcare model, allowing patients to receive necessary treatments without the need for frequent hospital or clinic visits. The increasing use of telemedicine and remote monitoring technologies supports self-care interventions. Pre-filled syringes can be prescribed during virtual consultations, and healthcare providers can remotely monitor patients' progress, offering guidance and adjustments to treatment plans as needed.

Additionally, the World Health Organization (WHO) estimates that 1 in 5 of the world’s population is now living in humanitarian crises, in which health systems are challenged to deliver essential services. Self-care interventions are tools that support the ability of individuals, families, and communities to promote health, prevent disease, maintain health, and cope with illness and disability with or without the support of a health worker.

Limited drug capacity is hampering the pre-filled syringes market's growth

The limited drug capacity of pre-filled syringes is expected to hamper the growth of the market due to several challenges that restrict their utility, especially for complex and large-volume drugs. Pre-filled syringes typically have a smaller drug capacity compared to vials and other packaging formats. This restricts their use of medications with specific dosage requirements. Many pre-filled syringes are designed for single-dose applications, often limiting the total volume to 1 to 2 mL.

For instance, according to the Diabetes Journals Organization, insulin syringes come in different sizes, including 0.3, 0.5, and 1.0 mL sizes that hold up to 30, 50, and 100 units of insulin, respectively. Insulin pre-filled syringes are limited to a maximum dose of around 1.0 mL due to syringe capacity constraints. This may not be sufficient for medications requiring larger doses.

Many biologics and high-concentration drugs require larger volumes for effective treatment, but pre-filled syringes are not always suitable due to limited capacity. The challenge is particularly pronounced with drugs used in oncology, where high concentrations and volumes are needed to maintain efficacy. For instance, the majority of pre-filled syringes on the market can hold up to 2 mL, which might not be sufficient for drugs like monoclonal antibodies and high-concentration biologics.

Pre-Filled Syringes Market Segment Analysis

The global pre-filled syringes market is segmented based on product, material, design, application, end-user, and region.

The needled prefilled syringes from the product type segment are expected to hold 64.71% of the market share in 2024 in the pre-filled syringes market

Needled pre-filled syringes are widely used for a range of applications, including insulin administration, vaccines, and biologic therapies. Insulin for diabetes management is a prime example where pre-filled syringes equipped with needles provide a reliable and convenient method for daily self-administration. Needled pre-filled syringes are preferred for their ability to deliver drugs directly into the bloodstream, ensuring effective therapeutic outcomes. The presence of a needle allows for precise dosing, which is crucial for biologics and therapies requiring targeted delivery. The major market players are focusing on the development of needled prefilled syringes, which is further boosting the segment’s growth.

For instance, in September 2024, BD released the BD Neopak XtraFlow Glass Prefillable Syringe and the latest capacity expansion of the BD Neopak Glass Prefillable Syringe platform to serve the growing market for biologic therapies. This solution features an 8-millimeter needle length and a thinner wall cannula to optimize subcutaneous delivery of higher viscosity drug profiles by reducing the injection force and time required for a fixed solution viscosity. The BD Neopak Glass Prefillable Syringe platform is designed to address key development needs for biologic drugs.

Advanced safety mechanisms integrated into needled pre-filled syringes improve their safety profile. These features have become essential in healthcare settings, especially for hospital administrations and for patient safety. For instance, in August 2024, Schreiner MediPharm introduced Needle-Trap Secu, a protection label with a newly integrated seal function that enhances sustainability and cost efficiency in the storage, transportation, and disposal of prefilled syringes. Its compact design technology effectively protects against needlestick injuries while saving space and resources.

Pre-Filled Syringes Market Geographical Analysis

North America is expected to dominate the global pre-filled syringes market with a 42.17% share in 2024

There is a growing trend towards self-administration in North America, especially in the United States, driven by the convenience it offers to patients and caregivers. Self-injection pens and needle-pre-filled syringes are widely used for managing chronic conditions like diabetes, rheumatoid arthritis, and multiple sclerosis. For instance, the National Institute of Health reports indicate that in the United States, approximately 40% of the population self-medicate, which further boosts the demand for prefilled syringes in the region.

North America is a major market for biologics and biosimilars, which are primarily delivered using pre-filled syringes. The growing prevalence of chronic diseases and the increasing adoption of biologics for treatment have driven the demand for pre-filled syringes in the region. Additionally, the presence of major market players in the region is also boosting the market growth with the development of advanced prefilled syringes.

For instance, in May 2025, Zydus Lifesciences Limited received final approval from the United States Food and Drug Administration (USFDA) for Glatiramer Acetate Injection, 20 mg/mL and 40 mg/mL, single-dose prefilled syringes.

Pre-Filled Syringes Market Top Companies

Top companies in the pre-filled syringes market include BD, Gerresheimer AG, Schott AG, Stevanato Group S.p.A., Terumo Corporation, Sanofi S.A., Hikma Pharmaceuticals PLC, MedXL Inc., West Pharmaceutical Services, Inc., and Cardinal Health, among others.

The global pre-filled syringes market report delivers a detailed analysis with 78 key tables, more than 71 visually impactful figures, and 149 pages of expert insights, providing a complete view of the market landscape.